Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons.

Show simple item record

dc.contributor.author Jong, Nancy en
dc.contributor.author Nakanishi, T en
dc.contributor.author Liu, Johnson en
dc.contributor.author Tamai, I en
dc.contributor.author McKeage, Mark en
dc.coverage.spatial United States en
dc.date.accessioned 2012-03-01T21:21:44Z en
dc.date.issued 2011 en
dc.identifier.citation The Journal of Pharmacology and Experimental Therapeutics 338(2):537-547 2011 en
dc.identifier.issn 0022-3565 en
dc.identifier.uri http://hdl.handle.net/2292/12526 en
dc.description.abstract The organic cation/carnitine transporters OCTN1 and OCTN2 are related to other organic cation transporters (OCT1, OCT2, and OCT3) known for transporting oxaliplatin, an anticancer drug with dose-limiting neurotoxicity. In this study, we sought to determine whether OCTN1 and OCTN2 also transported oxaliplatin and to characterize their functional expression and contributions to its neuronal accumulation and neurotoxicity in dorsal root ganglion (DRG) neurons relative to those of OCTs. [(14)C]Oxaliplatin uptake, platinum accumulation, and cytotoxicity were determined in OCTN-overexpressing human embryonic kidney (HEK) 293 cells and primary cultures of rat DRG neurons. Levels of mRNA and functional activities of rat (r)Octns and rOcts in rat DRG tissue and primary cultures were characterized using reverse transcription-polymerase chain reaction and uptake of model OCT/OCTN substrates, including [(3)H]1-methyl-4-phenylpyridinium (MPP(+)) (OCT1-3), [(14)C]tetraethylammonium bromide (TEA(+)) (OCT1-3 and OCTN1/2), [(3)H]ergothioneine (OCTN1), and [(3)H]l-carnitine (OCTN2). HEK293 cells overexpressing rOctn1, rOctn2, human OCTN1, and human OCTN2 showed increased uptake and cytotoxicity of oxaliplatin compared with mock-transfected HEK293 controls; in addition, both uptake and cytotoxicity were inhibited by ergothioneine and L-carnitine. The uptake of ergothioneine mediated by OCTN1 and of L-carnitine mediated by OCTN2 was decreased during oxaliplatin exposure. rOctn1 and rOctn2 mRNA was readily detected in rat DRG tissue, and they were functionally active in cultured rat DRG neurons, more so than rOct1, rOct2, or rOct3. DRG neuronal accumulation of [(14)C]oxaliplatin and platinum during oxaliplatin exposure depended on time, concentration, temperature, and sodium and was inhibited by ergothioneine and to a lesser extent by L-carnitine but not by MPP(+). Loss of DRG neuronal viability during oxaliplatin exposure was inhibited by ergothioneine but not by L-carnitine or MPP(+). OCTN1 and OCTN2 both transport oxaliplatin and are functionally expressed by DRG neurons. OCTN1-mediated transport of oxaliplatin appears to contribute to its neuronal accumulation and treatment-limiting neurotoxicity more so than OCTN2 or OCTs. en
dc.language eng en
dc.publisher American Society for Pharmacology and Experimental Therapeutics (ASPET) en
dc.relation.ispartofseries Journal of Pharmacology and Experimental Therapeutics en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0022-3565/ en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.subject Animals en
dc.subject Biological Transport, Active en
dc.subject Cells, Cultured en
dc.subject Female en
dc.subject Ganglia, Spinal en
dc.subject Gene Expression Regulation en
dc.subject HEK293 Cells en
dc.subject Humans en
dc.subject Neurons en
dc.subject Organic Cation Transport Proteins en
dc.subject Organoplatinum Compounds en
dc.subject Rats en
dc.subject Rats, Wistar en
dc.title Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. en
dc.type Journal Article en
dc.identifier.doi 10.1124/jpet.111.181297 en
pubs.issue 2 en
pubs.begin-page 537 en
pubs.volume 338 en
dc.rights.holder Copyright: American Society for Pharmacology and Experimental Therapeutics (ASPET) en
dc.identifier.pmid 21606177 en
pubs.end-page 547 en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Article en
pubs.elements-id 210372 en
pubs.org-id Medical and Health Sciences en
pubs.org-id Medical Sciences en
pubs.org-id Pharmacology en
pubs.org-id Science en
pubs.org-id Science Research en
pubs.org-id Maurice Wilkins Centre (2010-2014) en
dc.identifier.eissn 1521-0103 en
dc.identifier.pii jpet.111.181297 en
pubs.record-created-at-source-date 2012-02-14 en
pubs.dimensions-id 21606177 en


Files in this item

There are no files associated with this item.

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics